XURIDEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xuriden, and when can generic versions of Xuriden launch?
Xuriden is a drug marketed by Btg Intl and is included in one NDA.
The generic ingredient in XURIDEN is uridine triacetate. There are thirty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.
Summary for XURIDEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Patent Applications: | 330 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for XURIDEN |
What excipients (inactive ingredients) are in XURIDEN? | XURIDEN excipients list |
DailyMed Link: | XURIDEN at DailyMed |
Pharmacology for XURIDEN
Ingredient-type | Analogs/Derivatives Pyrimidines |
Drug Class | Pyrimidine Analog |
Anatomical Therapeutic Chemical (ATC) Classes for XURIDEN
US Patents and Regulatory Information for XURIDEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Btg Intl | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XURIDEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Btg Intl | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XURIDEN
See the table below for patents covering XURIDEN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 1071577 | ⤷ Try a Trial | |
Japan | 2008007525 | PYRIMIDINE NUCLEOTIDE PRECURSOR FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | ⤷ Try a Trial |
Israel | 114887 | ⤷ Try a Trial | |
Norway | 892642 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XURIDEN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1849470 | 2017/033 | Ireland | ⤷ Try a Trial | PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160425 |
2207786 | 2023C/550 | Belgium | ⤷ Try a Trial | PRODUCT NAME: CEDAZURIDINE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230918 |
2207786 | LUC00326 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMPOSITION COMPRENANT: DE LA CEDAZURIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; ET DE LA DECITABINE; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230913 |
2207786 | LUC00327 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: CEDAZURIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230918 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |